Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 6/20 | 1.00 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.73 |
| ▸ | CHRNA5 | P30532 | 3/20 | 0.73 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.66 |
| ▸ | NPC1 | O15118 | 6/20 | 0.66 |
| ▸ | RAB9A | P51151 | 6/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.66 |
| ▸ | TP53 | P04637 | 4/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | HPGD | P15428 | 2/20 | 0.66 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.62 |
| ▸ | RELA | Q04206 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1422890 | 0.85 | CHRNB2 (1.00) | PPARACHRNB2CHRNA5CHRNA4SMN1; SMN2 | |
| SCHEMBL2463534 | 0.82 | SMN1; SMN2 (0.93) | PPARACHRNB2CHRNA5CHRNA4SMN1; SMN2 | |
| SCHEMBL3685718 | 0.81 | CHRNB2 (0.83) | PPARACHRNB2CHRNA5CHRNA4SMN1; SMN2 | |
| SCHEMBL3796996 | 0.79 | SMN1; SMN2 (1.00) | PPARACHRNB2CHRNA5CHRNA4SMN1; SMN2 | |
| SCHEMBL12117531 | 0.78 | PPARA (0.63) | PPARASMN1; SMN2ALDH1A1TP53MAPT | |
| SCHEMBL31141579 | 0.78 | PPARA (0.63) | PPARASMN1; SMN2ALDH1A1TP53MAPT | |
| SCHEMBL3430263 | 0.78 | NPC1 (0.79) | PPARACHRNB2CHRNA5CHRNA4SMN1; SMN2 | |
| SCHEMBL5959951 | 0.78 | SMN1; SMN2 (0.84) | PPARACHRNB2CHRNA5CHRNA4SMN1; SMN2 | |
| SCHEMBL1423193 | 0.78 | CHRNB2 (0.83) | PPARACHRNB2CHRNA5CHRNA4SMN1; SMN2 | |
| SCHEMBL5959911 | 0.77 | NPC1 (0.77) | PPARACHRNB2CHRNA5CHRNA4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294856-A1 | NOVEL OXADIAZOLE DERIVATIVES AND THEIR MEDICAL USE | DAHL BJARNE H (DK) | 2011-12-01 | — | — | US | claimed |
| EP-2255848-A2 | Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer | NeuroSearch AS (DK) | 2010-12-01 | — | — | EP | claimed |
| US-20100234349-A1 | PHARMACEUTICAL COMBINATIONS OF A NICOTINE RECEPTOR MODULATOR AND A COGNITIVE ENHANCER | NEUROSEARCH A/S (DK) | 2010-09-16 | — | — | US | claimed |
| US-20090312347-A1 | Novel oxadiazole derivatives and their medical use | SANIONA A/S (DK) | 2009-12-17 | — | — | US | claimed |
| EP-2083921-A2 | PHARMACEUTICAL COMBINATIONS OF A NICOTINE RECEPTOR MODULATOR AND A COGNITIVE ENHANCER | NEUROSEARCH A/S (DK) | 2009-08-05 | — | — | EP | claimed |
| WO-2008028903-A2 | PHARMACEUTICAL COMBINATIONS OF A NICOTINE RECEPTOR MODULATOR AND A COGNITIVE ENHANCER | NEUROSEARCH A/S (DK) | 2008-03-13 | — | — | WO | claimed |
| EP-1881979-A1 | NOVEL OXADIAZOLE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2008-01-30 | — | — | EP | claimed |
| WO-2006114400-A1 | NOVEL OXADIAZOLE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2006-11-02 | — | — | WO | claimed |
| US-20110294856-A1 | NOVEL OXADIAZOLE DERIVATIVES AND THEIR MEDICAL USE | DAHL BJARNE H (DK) | 2011-12-01 | — | — | US | disclosed |
| US-8017631-B2 | Oxadiazole derivatives and their medical use | NEUROSEARCH A/S (DK) | 2011-09-13 | — | — | US | disclosed |
| EP-2255848-A2 | Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer | NeuroSearch AS (DK) | 2010-12-01 | — | — | EP | disclosed |
| US-20100234349-A1 | PHARMACEUTICAL COMBINATIONS OF A NICOTINE RECEPTOR MODULATOR AND A COGNITIVE ENHANCER | NEUROSEARCH A/S (DK) | 2010-09-16 | — | — | US | disclosed |
| US-20090312347-A1 | Novel oxadiazole derivatives and their medical use | SANIONA A/S (DK) | 2009-12-17 | — | — | US | disclosed |
| EP-2083921-A2 | PHARMACEUTICAL COMBINATIONS OF A NICOTINE RECEPTOR MODULATOR AND A COGNITIVE ENHANCER | NEUROSEARCH A/S (DK) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008028903-A2 | PHARMACEUTICAL COMBINATIONS OF A NICOTINE RECEPTOR MODULATOR AND A COGNITIVE ENHANCER | NEUROSEARCH A/S (DK) | 2008-03-13 | — | — | WO | disclosed |
| EP-1881979-A1 | NOVEL OXADIAZOLE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2008-01-30 | — | — | EP | disclosed |
| WO-2006114400-A1 | NOVEL OXADIAZOLE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312347-A1 | Novel oxadiazole derivatives and their medical use | CHRNA3, CHRNA5, CHRNB3 | PPARA 554/4885CHRNB2 10/4885CHRNA5 2/4885 |
| US-20100234349-A1 | PHARMACEUTICAL COMBINATIONS OF A NICOTINE RECEPTOR MODULATOR AND A COGNITIVE ENHANCER | CHRNA10, CHRNA4, CHRNA5 | PPARA 213/4885CHRNB2 12/4885CHRNA5 3/4885 |
| US-20110294856-A1 | NOVEL OXADIAZOLE DERIVATIVES AND THEIR MEDICAL USE | CHRNA3, CHRNA5, CHRNB3 | PPARA 554/4885CHRNB2 10/4885CHRNA5 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.